

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,900

Open access books available

185,000

International authors and editors

200M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com



Mediastinal Parathyroidectomy: Preoperative Management of Hyperparathyroidism

Dariusz Sagan^{1*}, Jerzy S. Tarach², Andrzej Nowakowski², Maria Klatka³,
Elżbieta Czekajska-Chehab⁴, Andrzej Drop⁴,
Beata Chrapko⁵ and Janusz Klatka⁶

¹Department of Thoracic Surgery,

²Department of Endocrinology,

³Department of Paediatric Endocrinology and Neurology,

⁴1st Department of Radiology,

⁵Department of Nuclear Medicine,

⁶Department of Otolaryngology and Laryngeal Oncology,
Medical University of Lublin,
Poland

1. Introduction

1.1 Anatomy and embryology of parathyroid glands

The normal parathyroid gland is oval or spherical in shape, has a distinct yellowish color, and averages 2x3x7 mm. The total mean weight of four normal parathyroids is about 150 mg. Majority of the population have four parathyroid glands typically located at the posterior capsule of the thyroid gland (Fig. 1; Fig.2), however in nearly 15% of individuals more than four glands are present. Phylogenetically, the parathyroid glands appear in amphibia, and arise from pharyngeal pouches III and IV. They may be arrested in the development as high as




Fig. 1. Thyroid & parathyroid anatomy




Fig. 2. Parathyroid glands anatomy. Left side view

at the level of the hyoid bone on the way of their descent to their typical location. Occasionally, parathyroids may be incorporated into the thyroid gland or thymus (intrathyroidal or mediastinal location). Lower (inferior) parathyroid glands (parathyroid III) may be found in the anterior mediastinum, while the upper (superior) parathyroids (parathyroid IV) usually remain in close association with the upper portion of the lateral thyroid lobes but may descend caudally along the esophagus into the posterior mediastinum (Fig. 3).




Fig. 3. Computed tomography scan showing a large mediastinal parathyroid adenoma (indicated with an arrow)

The parathyroid glands may lie in front of or behind the internal jugular vein and common carotid artery. Parathyroids are usually supplied by a branch of the inferior thyroid artery but may be supplied by the superior thyroid or, rarely, the thyroid ima arteries. The vessels can be seen entering a hilum-like structure, a feature that may be practically utilized to differentiate parathyroid glands from fat.

2. Physiology

Parathyroid glands secrete parathyroid hormone (PTH), which together with vitamin D, and calcitonin plays a vital role in precise regulation of calcium and phosphorus metabolism in

bone, kidney, and gut. PTH and calcitonin work in concert to regulate plasma levels of ionized calcium. Fall in the ionized calcium level stimulates the parathyroids to secrete more PTH, and inhibits the parafollicular cells within the thyroid to produce less calcitonin. The rise in PTH and fall in calcitonin stimulate increased resorption of calcium in the renal tubules and from bones, thus more calcium enters the blood, and ionized calcium levels normalize. PTH in the blood stream is heterogeneous and consists of the intact hormone, the amino terminal (N-terminal) fragment and the carboxyl terminal (C-terminal) fragment. C-terminal fragment is biologically inert, whereas N-terminal fragment maintains hormonal activity, however substantially lower than the intact hormone. Currently available diagnostic tests are capable of intact hormone level determination, which is important for reliability of the measurement in particular for intraoperative use.

3. Primary hyperparathyroidism

Primary hyperparathyroidism is a disease characterized by autonomous overproduction of PTH resulting in hypercalcemia. In majority of cases it is caused by a single parathyroid adenoma (80-85%), and less frequently by hyperplasia (10%), multiple adenomas (6%), or carcinoma (1%). Currently, primary hyperparathyroidism occurs in 0.1-0.3% of the general population and in unselected patients is considered the most common cause of hypercalcemia. It is almost three times more common in women than in men, with peak incidence between the third and fifth decades.

Excess production of PTH results in mobilization of calcium from bone and inhibition of the renal reabsorption of phosphate, leading to hypercalcemia and hypophosphatemia. Besides, it causes a wasting of calcium and phosphorus, which eventually may result in osseous mineral loss and osteoporosis. Other conditions which may be associated with hyperparathyroidism include nephrocalcinosis, nephrolithiasis, osteitis fibrosa cystica, pancreatitis, peptic ulcer, hypertension, and gout. Diagnosis of any of these diseases should evoke suspicion for hyperparathyroidism and the patient should be referred for more precise tests.

Hyperparathyroidism is occasionally associated with multiple endocrine neoplasia (MEN) type 1, or type 2. MEN type 1 is characterized by tumors of the parathyroid, pituitary, and pancreas (hyperparathyroidism, pituitary tumors, and islet cell pancreatic tumors) that may lead to gastrinoma (Zollinger-Ellison syndrome), glucagonoma, insulinoma (hypoglycemia), somatostatinoma, lipoma and pancreatic polypeptide tumors (PPomas). Adrenocortical tumors, carcinoid tumors, and multiple lipomas have also been reported in these patients. MEN type 2 is divided into 2 subtypes: MEN 2a and MEN 2b. MEN 2a is characterized by hyperparathyroidism associated with pheochromocytoma and thyroid medullary carcinoma. Hyperparathyroidism is rare in MEN 2b patients who often have multiple neuromas and a marfanoid habitus.

Parathyroid adenomas may range in weight from 65 mg to over 35 g, but occasionally the weight of these tumors may exceed 35g. Usually the size of the tumor parallels the degree of hypercalcemia (the larger the tumor, the more severe hypercalcemia). Microscopic examination of parathyroid adenomas shows chief cell, water cell, or, rarely, oxyphil cell type.

Primary parathyroid hyperplasia may be another cause of hyperparathyroidism. This condition involves all of the parathyroid glands, which vary considerably in size but are usually larger than normal. Microscopic examination may reveal two types: chief cell

hyperplasia and water-clear cell hyperplasia. Parathyroid carcinoma is rare but usually leads to severe hypercalcemia, and should be suspected at operation when the parathyroid gland is hard, has a whitish or irregular capsule, or shows signs of invasiveness. Rupture of the parathyroid tumor or breaching of the tumor capsule during rough dissection may result in seeding hyperactive tissue. This, and less frequently multiple embryologic rests may lead to a rare condition called parathyromatosis characterized by persistent hypercalcemia.

4. Signs and symptoms

Clinical signs and symptoms of hyperparathyroidism range from barely recognizable by patients, like muscle fatigability, weakness, psychiatric disturbances, constipations, polydipsia and polyuria to severely impairing normal activities, like bone and muscle pains, nephrolithiasis, nephrocalcinosis, hypertension, peptic ulcer, pancreatitis or gout. Osteitis fibrosa cystica with bone pains and deformities, which was a prevailing symptom in patients with hyperparathyroidism a few decades ago, now became less frequent because majority of cases are detected early in the course of the disease. Also the incidence of renal complications decreased markedly and many patients are diagnosed by routine screening while still asymptomatic.

5. Laboratory tests

Serum calcium, parathyroid hormone and phosphates level are the principal laboratory tests used for the diagnosis of hyperparathyroidism. Elevated serum calcium and low phosphates are highly suggestive of hyperparathyroidism, however in about 50% of patients serum phosphates level is normal. Measurement of serum intact parathyroid hormone (PTH) concentration is the key test in diagnostic workout for patients with hypercalcemia, because the PTH level is low or nil in all cases except for those caused by primary hyperparathyroidism and familial hypocalciuric hypercalcemia, where PTH is markedly elevated.

Complementary laboratory tests include chlorides, protein electrophoretic pattern, alkaline phosphatase, creatinine, uric acid and urea nitrogen, urinary calcium, blood hematocrite and pH, serum magnesium and ESR. Sometimes, when previous tests are equivocal, measurement of nephrogenous cAMP, 1,25-hydroxy vitamin D levels and tubular resorption of phosphates may be helpful. Serum chloride concentration is elevated in nearly half of patients with hyperparathyroidism and may be a useful diagnostic clue. It's due to direct influence of PTH on the proximal renal tubule decreasing the resorption of bicarbonate, which leads to increased resorption of chloride. Other causes of hypercalcemia do not give rise in chloride concentration.

6. Secondary hyperparathyroidism

Secondary hyperparathyroidism (sHPT) is a condition characterized by excess secretion of parathyroid hormone stimulated by external factors, mainly hypocalcemia. Chronic renal failure is the most common cause of secondary hyperparathyroidism, as it results in hypocalcemia due to impaired conversion of vitamin D into active form, and excessive loss of calcium with urine. Sporadically sHPT may be caused by malabsorption, like chronic

pancreatitis, small bowel disease or malabsorption-dependent bariatric surgery. Prolonged stimulation of parathyroid tissue by hypocalcemia results in enlargement of parathyroids in the form of their hyperplasia and less frequently parathyroid adenoma.

7. Tertiary hyperparathyroidism

Tertiary hyperparathyroidism (tHPT) is a condition of autonomic excessive secretion of parathyroid hormone developing from secondary parathyroidism, that maintains despite restoration of renal function. It is caused by development of autonomous (unregulated) parathyroid function following a prolonged period of persistent parathyroid stimulation. It is no longer responsive to treatment by medication and requires surgical removal of three and a half parathyroid glands.

8. Indications for surgical treatment

Parathyroidectomy is currently recognized as the treatment of choice for patients with primary hyperparathyroidism. For virtually all these patients surgical resection of hyperactive parathyroid tissue is curative. It provides both metabolic improvement and symptoms relief. Medical observation is contraindicated. Furthermore, parathyroidectomy is recommended as early as possible in the course of the disease because once systemic complications such as renal dysfunction or hypertension develop, they tend to progress despite elimination of the underlying hyperparathyroidism.

9. Preoperative imaging techniques

Various techniques are currently available for parathyroid glands imaging. Noninvasive studies include ultrasonography, scintigraphy, computed tomography (CT) scanning, and magnetic resonance imaging (MRI). Scintigraphy with use of the radiopharmaceuticals technetium ^{99m}Tc sestamibi or technetium ^{99m}Tc tetrofosmin is widely recommended as the preferred imaging technique for parathyroids. Parathyroid selective arteriography or selective parathyroid venous sampling have been used occasionally as invasive techniques in select cases.

9.1 Ultrasonography

Parathyroid ultrasonography is currently the most easily accessible and a relatively inexpensive non-invasive test that is routinely used for the assessment of the thyroid and parathyroid glands. It is utilized for preoperative investigation in patients with hyperparathyroidism not only to localize and visualize enlarged parathyroids, but also to rule out thyroid nodules that may need to be evaluated prior to parathyroid surgery. For best results a high-frequency (7.5- or 10-MHz) linear ultrasound transducer should be available. The patient should be supine with the neck moderately hyperextended. It is recommended to start the evaluation from the carotid bifurcation superiorly and proceed down to the sternal notch inferiorly and to the carotid artery laterally.

Normal parathyroids are barely visualized with ultrasonography. Parathyroid adenomas appear on gray-scale images as hypoechoic or anechoic, discrete, oval masses. They are located posterior to the lobe of the thyroid gland and anterior to the longus colli muscles. Usually, the common carotid artery confines the parathyroid-bearing region laterally. An

echogenic line separating the thyroid tissue from the enlarged parathyroid gland can be often visualized. Cystic changes, lobulations, increased echogenicity due to fatty deposition, and occasional calcifications are more frequent in larger adenomas.

Parathyroid adenomas, in particular lesions larger than 1 cm in diameter, tend to be hypervascular, and therefore color Doppler ultrasonography is useful in localizing these enlarged glands. Besides, Doppler ultrasound can easily disclose the extrathyroidal vessel supplying parathyroid and this finding may constitute a road map to the otherwise inconspicuous gland.

Ultrasonography is efficient in diagnosing cervical parathyroid lesions with reported sensitivity up to 80% and specificity up to 90%, but fails to detect majority of parathyroid adenomas located in the mediastinum. Additionally, intrathyroidal lesions cannot be differentiated as a parathyroid adenoma or thyroid nodule based on imaging only, and a biopsy is required.

9.2 ^{99m}Tc sestamibi imaging

Nuclear imaging with use of ^{99m}Tc sestamibi is currently approved as a standard technique for preoperative imaging of parathyroid glands. ^{99m}Tc sestamibi is a complex of the radioisotope technetium- ^{99m}Tc with the ligand methoxyisobutylisonitrile (MIBI). ^{99m}Tc sestamibi, first applied as a myocardial perfusion agent, for parathyroids assessment is combined with either sodium iodide I^{123} or ^{99m}Tc pertechnetate in a procedure called subtraction scintigraphy. It is based on a phenomenon that ^{99m}Tc sestamibi is accumulated by both thyroid and abnormal parathyroids, whereas sodium iodide I^{123} and ^{99m}Tc pertechnetate are taken up by only thyroid tissue. To visualize parathyroids and differentiate them from thyroid tissue the sodium iodide I^{123} or ^{99m}Tc -pertechnetate image is subtracted from the ^{99m}Tc -sestamibi image.

Another, more recent imaging modality is the dual-phase technique with ^{99m}Tc sestamibi as the sole imaging agent. Both thyroid tissue and abnormal parathyroid tissue incorporate ^{99m}Tc sestamibi from circulating blood rapidly after intravenous administration. The test is based on the differential washout of ^{99m}Tc sestamibi from thyroid compared with abnormal parathyroids. The rate of washout from hyperactive parathyroid tissue, such as parathyroid adenoma, is much slower than that of normal thyroid tissue. Routine protocol includes intravenous administration of 20mCi of ^{99m}Tc Sestamibi and sequential acquisition of early and delayed images of the neck and upper mediastinum. The early image, obtained 10-15 minutes after the injection, is called the thyroid phase as ^{99m}Tc sestamibi is rapidly taken up in the thyroid gland at this time. 1.5-3 hours after the injection the delayed image called the parathyroid phase is recorded. At this phase, ^{99m}Tc sestamibi has been washed out from thyroid but remains accumulated in the hyperactive parathyroid tissue, and this allows for localization of abnormal parathyroid glands. Planar images may be complemented with lateral or oblique acquisitions, or even SPECT images when appropriate equipment is applied. Sensitivity of the ^{99m}Tc sestamibi dual phase protocol has been reported to achieve 70-100%. Small or pedunculated, mobile adenomas may, however, be missed at this test.

^{99m}Tc sestamibi may also be used in minimally invasive parathyroid surgery, as an intraoperative adjunct facilitating localization of hyperactive parathyroid adenoma and confirming curative resection. The radionuclide is injected 1.5 to 3 hours prior to surgery, and a hand-held gamma probe is used to guide the incision, localize the abnormal gland and confirm identity of the resected parathyroid tissue ex-vivo. This technique called

intraoperative nuclear mapping proved to be successful, and is a standard procedure in a number of centers.

^{99m}Tc tetrofosmin is another radiopharmaceutical agent recently introduced into parathyroid imaging. It has a slightly different mechanism of accumulation in tissues, but imaging characteristics similar to those of ^{99m}Tc sestamibi. Also imaging protocols are similar with intravenous injections of 20-25 mCi of radionuclide prior to early (10-30 minutes) and delayed (1.5-3 hours) acquisition images.

9.3 Computed tomography (CT) scanning

Assessment of parathyroid glands with use of a typical CT protocol involves the acquisition of contiguous axial 2- to 3-mm images ranging from the hyoid bone down to the carina. Nonenhanced images of parathyroid adenomas have an attenuation similar to that of muscle. Substantial degree of enhancement is usually shown in parathyroid adenomas after administration of contrast material, as these lesions tend to be hypervascular structures. Typically, parathyroid adenomas present at CT as enlarged, enhancing, soft-tissue masses in the expected location of the parathyroids. The sensitivity of CT in detecting parathyroid adenomas attains 90%. However, the use of ionizing radiation and required intravenous administration of contrast material accompanied by associated risks are considered remarkable disadvantages of this imaging technique. Besides, thyroid nodule, tortuous vessel, or laterally displaced esophagus may be misidentified as a false-positive finding, whereas small or ectopic lesion, poor visualization of neck structures or distorted neck anatomy due to prior surgery may lead to false-negative result.

9.4 Magnetic resonance imaging

MRI is occasionally used for parathyroid imaging. A typical MRI protocol for the assessment of parathyroids involves axial images of the neck and mediastinum. Images are acquired using T1-weighted spin-echo sequences (short recovery time [TR], short echo time [TE]) followed by T2-weighted spin-echo sequences (long TR, long TE). Parathyroid adenomas are seen on MRI images as soft-tissue masses, whereas normal parathyroids are usually not detected. Parathyroid adenomas commonly have low-to-medium signal intensity on T1-weighted images and high signal intensity on T2-weighted images. After gadolinium contrast administration, abnormal parathyroid glands show strong enhancement on T1-weighted images, comparable to conventional T2-weighted imaging.

9.5 Parathyroid arteriography and venous sampling

Parathyroid arteriography and parathyroid venous sampling are invasive tests burdened by a remarkable risk of embolic stroke and spinal cord injury, and therefore should be considered only when the findings of noninvasive imaging modalities are nondiagnostic. Parathyroid adenomas, like many endocrine tumors, tend to be hypervascular and have a characteristic appearance on angiograms. They appear as round or oval lesions with smooth margins and dense vascular blush. Localization of parathyroid adenoma may be visualized with use of digital subtraction angiography (DSA) and/or conventional arteriography. Thyrocervical trunks and common carotid arteries should be subject to selective arteriography in typical cases. Ectopic mediastinal or thymic glands may be better identified by examination of internal thoracic arteries.

Selective venous sampling with parathyroid hormone measurement may be performed to determine the general location of hypersecreting parathyroid tissue. Right and left thymic veins, inferior thyroid veins, and vertebral veins have been reported to be sampled in this regimen. A 2-fold gradient in PTH concentration in the sampled vein as referenced to that of the peripheral vein confirms the location of hyperactive parathyroid tissue. Similar technique may also be used intraoperatively to confirm curative resection of parathyroid adenoma.

10. Preoperative anesthetic management

Since renal function is likely to be impaired in hyperparathyroidism, prior to surgical treatment hypercalcemic patients require thorough rehydration. In some of these patients urinary catheterization and central venous pressure monitoring may be indicated. After rehydration, loop diuretics may be administered to decrease renal calcium reabsorption and promote urinary excretion, which in result will alleviate hypercalcaemia. Excessive diuresis may in turn lead to increased maintenance fluid requirements. Corticosteroids, bisphosphonates, calcium chelators such as trisodium edentate, calcitonin, or even dialysis are occasionally indicated in severe cases. Hypertension, if present, should be controlled with fast-acting antihypertensive medication. In patients with end-stage renal failure, perioperative invasive central venous pressure monitoring may be helpful for thorough monitoring of circulatory system. Occasionally, tumors of other organs may secrete PTH, for example, bronchial or tracheal carcinomas. This condition is called pseudohyperparathyroidism and should be brought to attention preoperatively to avoid intraoperative ventilatory problems in these rare cases when the lesion occludes bronchial or tracheal lumen.

11. References

- [1] Fernández-Fernández FJ, Sesma P. Primary hyperparathyroidism. *N Engl J Med*. 2012 Mar 1;366(9):860; author reply 860-1.
- [2] Afzal A, Gauhar TM, Butt WT, Khawaja AA, Azim KM. Management of hyperparathyroidism: a five year surgical experience. *J Pak Med Assoc*. 2011 Dec;61(12):1194-8.
- [3] Wang CC, Hsu YJ, Wu CC, Yang SS, Chen GS, Lin SH, Chu P. Serum fetuin-A levels increased following parathyroidectomy in uremic hyperparathyroidism. *Clin Nephrol*. 2012 Feb;77(2):89-96. doi: 10.1054/CN106757.
- [4] Emilion E, Emilion R. Estimation of the 25(OH) vitamin D threshold below which secondary hyperparathyroidism may occur among African migrant women in Paris. *Int J Vitam Nutr Res*. 2011 Jul;81(4):218-24.
- [5] Francucci CM, Ceccoli L, Caudarella R, Rilli S, Vescini F, Boscaro M. Asymptomatic primary hyperparathyroidism: surgical and medical management. *J Endocrinol Invest*. 2011 Jul;34(7 Suppl):50-4.
- [6] Nuti R, Merlotti D, Gennari L. Vitamin D deficiency and primary hyperparathyroidism. *J Endocrinol Invest*. 2011 Jul;34(7 Suppl):45-9. Review.
- [7] Pepe J, Cipriani C, Pilotto R, De Lucia F, Castro C, Lenge L, Russo S, Guarnieri V, Scillitani A, Carnevale V, D'Erasmo E, Romagnoli E, Minisola S. Sporadic and

- hereditary primary hyperparathyroidism. *J Endocrinol Invest.* 2011 Jul;34(7 Suppl):40-4. Review.
- [8] Cetani F, Pardi E, Borsari S, Marcocci C. Molecular pathogenesis of primary hyperparathyroidism. *J Endocrinol Invest.* 2011 Jul;34(7 Suppl):35-9. Review.
- [9] Francucci CM, Ghigo E, Boscaro M. Primary hyperparathyroidism and skeleton. Foreword. *J Endocrinol Invest.* 2011 Jul;34(7 Suppl):1-2.
- [10] Ardito G, Revelli L, Giustozzi E, Giordano A. Radioguided parathyroidectomy in forearm graft for recurrent hyperparathyroidism. *Br J Radiol.* 2012 Jan;85(1009):e1-3.
- [11] Peiris AN, Youssef D, Grant WB. Secondary hyperparathyroidism: benign bystander or culpable contributor to adverse health outcomes? *South Med J.* 2012 Jan;105(1):36-42. Review.
- [12] Marcocci C, Cetani F. Clinical practice. Primary hyperparathyroidism. *N Engl J Med.* 2011 Dec 22;365(25):2389-97.
- [13] Piedra M, García-Unzueta MT, Berja A, Paule B, Lavín BA, Valero C, Riancho JA, Amado JA. "Single nucleotide polymorphisms of the OPG/RANKL system genes in primary hyperparathyroidism and their relationship with bone mineral density". *BMC Med Genet.* 2011 Dec 20;12:168.
- [14] Duh QY. The Bayes theorem wins: comment on "Impact of localization studies and clinical scenario in patients with hyperparathyroidism being evaluated for reoperative neck surgery". *Arch Surg.* 2011 Dec;146(12):1403.
- [15] Shin JJ, Milas M, Mitchell J, Berber E, Ross L, Siperstein A. Impact of localization studies and clinical scenario in patients with hyperparathyroidism being evaluated for reoperative neck surgery. *Arch Surg.* 2011 Dec;146(12):1397-403.
- [16] Sorensen MD, Duh QY, Grogan RH, Tran TC, Stoller ML. Urinary parameters as predictors of primary hyperparathyroidism in patients with nephrolithiasis. *J Urol.* 2012 Feb;187(2):516-21. Epub 2011 Dec 15.
- [17] Shlapack MA, Rizvi AA. Normocalcemic primary hyperparathyroidism-characteristics and clinical significance of an emerging entity. *Am J Med Sci.* 2012 Feb;343(2):163-6. Review.
- [18] Bhadada SK, Bhansali A, Shah VN, Rao DS. Changes in serum leptin and adiponectin concentrations and insulin resistance after curative parathyroidectomy in moderate to severe primary hyperparathyroidism. *Singapore Med J.* 2011 Dec;52(12):890-3.
- [19] Wang TS, Cheung K, Farrokhyar F, Roman SA, Sosa JA. Would scan, but which scan? A cost-utility analysis to optimize preoperative imaging for primary hyperparathyroidism. *Surgery.* 2011 Dec;150(6):1286-94.
- [20] Perrier ND, Evans DB. Population-level predictors of persistent hyperparathyroidism. *Surgery.* 2011 Dec;150(6):1120-1.
- [21] Yeh MW, Wiseman JE, Chu SD, Ituarte PH, Liu IL, Young KL, Kang SJ, Harari A, Haigh PI. Population-level predictors of persistent hyperparathyroidism. *Surgery.* 2011 Dec;150(6):1113-9.
- [22] Wallace LB, Parikh RT, Ross LV, Mazzaglia PJ, Foley C, Shin JJ, Mitchell JC, Berber E, Siperstein AE, Milas M. The phenotype of primary hyperparathyroidism with normal parathyroid hormone levels: how low can parathyroid hormone go? *Surgery.* 2011 Dec;150(6):1102-12.

- [23] Press D, Politz D, Lopez J, Norman J. The effect of vitamin D levels on postoperative calcium requirements, symptomatic hypocalcemia, and parathormone levels following parathyroidectomy for primary hyperparathyroidism. *Surgery*. 2011 Dec;150(6):1061-8.
- [24] Mshelia DS, Hatutale AN, Mokgoro NP, Nchabaleng ME, Buscombe JR, Sathekge MM. Correlation between serum calcium levels and dual-phase (99m)Tc-sestamibi parathyroid scintigraphy in primary hyperparathyroidism. *Clin Physiol Funct Imaging*. 2012 Jan;32(1):19-24. doi: 10.1111/j.1475-097X.2011.01048.x. Epub 2011 Aug 24.
- [25] Lumachi F, Camozzi V, Luisetto G, Zanella S, Basso SM. Arterial blood pressure, serum calcium and PTH in elderly men with parathyroid tumors and primary hyperparathyroidism. *Anticancer Res*. 2011 Nov;31(11):3969-72.
- [26] El-Shafey EM, Alsahow AE, Alsaran K, Sabry AA, Atia M. Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients. *Ther Apher Dial*. 2011 Dec;15(6):547-55. doi: 10.1111/j.1744-9987.2011.00994.x.
- [27] Cheungpasitporn W, Suksaranjit P, Chanprasert S. Acute kidney injury from bilateral ureteral calcium stones in the setting of primary hyperparathyroidism. *Am J Emerg Med*. 2012 Feb;30(2):383-4. Epub 2011 Nov 17.
- [28] Schmidt MC, Kahraman D, Neumaier B, Ortmann M, Stippel D. Tc-99m-MIBI-negative parathyroid adenoma in primary hyperparathyroidism detected by C-11-methionine PET/CT after previous thyroid surgery. *Clin Nucl Med*. 2011 Dec;36(12):1153-5.
- [29] Sanadgol H, Bayani M, Mohammadi M, Bayani B, Mashhadi MA. Effect of vitamin C on parathyroid hormone in hemodialysis patients with mild to moderate secondary hyperparathyroidism. *Iran J Kidney Dis*. 2011 Nov;5(6):410-5.
- [30] Carneiro-Pla D, Solorzano C. A summary of the new phenomenon of normocalcemic hyperparathyroidism and appropriate management. *Curr Opin Oncol*. 2012 Jan;24(1):42-5.
- [31] Suwan N. Secondary hyperparathyroidism and risk factors in patients undergoing peritoneal dialysis in a tertiary hospital. *J Med Assoc Thai*. 2011 Sep;94 Suppl 4:S101-5.
- [32] Iwata S, Walker MD, Di Tullio MR, Hyodo E, Jin Z, Liu R, Sacco RL, Homma S, Silverberg SJ. Aortic valve calcification in mild primary hyperparathyroidism. *J Clin Endocrinol Metab*. 2012 Jan;97(1):132-7. Epub 2011 Oct 26.
- [33] Amin AL, Wang TS, Wade TJ, Quiroz FA, Hellman RS, Evans DB, Yen TW. Nonlocalizing imaging studies for hyperparathyroidism: where to explore first? *J Am Coll Surg*. 2011 Dec;213(6):793-9. Epub 2011 Oct 19.
- [34] Pilz S, Kienreich K, Drechsler C, Ritz E, Fahrleitner-Pammer A, Gaksch M, Meinitzer A, März W, Pieber TR, Tomaschitz A. Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GEOCOH study. *J Clin Endocrinol Metab*. 2012 Jan;97(1):E75-9. Epub 2011 Oct 19.
- [35] Jabiev AA, Lew JL, Garb JL, Sanchez YM, Solorzano CC. Primary hyperparathyroidism in the underinsured: a study of 493 patients. *Surgery*. 2012 Mar;151(3):471-6. Epub 2011 Oct 13.


- [36] Wilson SD, Doffek KM, Wang TS, Krzywda EA, Evans DB, Yen TW. Primary hyperparathyroidism with a history of head and neck irradiation: the consequences of associated thyroid tumors. *Surgery*. 2011 Oct;150(4):869-77.
- [37] Lu KC, Wu CC, Ma WY, Chen CC, Wu HC, Chu P. Decreased blood lead levels after calcitriol treatment in hemodialysis patients with secondary hyperparathyroidism. *Bone*. 2011 Dec;49(6):1306-10. Epub 2011 Oct 1.
- [38] Witteveen JE, van Lierop AH, Papapoulos SE, Hamdy NA. Increased circulating levels of FGF23: an adaptive response in primary hyperparathyroidism? *Eur J Endocrinol*. 2012 Jan;166(1):55-60. Epub 2011 Oct 7.
- [39] Udelsman R. Approach to the patient with persistent or recurrent primary hyperparathyroidism. *J Clin Endocrinol Metab*. 2011 Oct;96(10):2950-8.
- [40] Bollerslev J, Marcocci C, Sosa M, Nordenström J, Bouillon R, Mosekilde L. Current evidence for recommendation of surgery, medical treatment and vitamin D repletion in mild primary hyperparathyroidism. *Eur J Endocrinol*. 2011 Dec;165(6):851-64. Epub 2011 Sep 29.
- [41] Adachi M, Miyoshi T, Shiraishi N, Shimada H, Sakaguchi S, Tomita K, Kitamura K. A study of maintenance therapy after intravenous maxacalcitol for secondary hyperparathyroidism. *Clin Nephrol*. 2011 Oct;76(4):266-72.
- [42] Ishimura E, Okuno S, Tsuboniwa N, Ichii M, Yamakawa K, Yamakawa T, Shoji S, Nishizawa Y, Inaba M. Effect of cinacalcet on bone mineral density of the radius in hemodialysis patients with secondary hyperparathyroidism. *Clin Nephrol*. 2011 Oct;76(4):259-65.
- [43] Shapey IM, Jaunoo SS, Hanson C, Jaunoo SR, Thrush S, Munro A. Primary hyperparathyroidism: how many cases are being missed? *Ann R Coll Surg Engl*. 2011 May;93(4):294-6.
- [44] Pyram R, Mahajan G, Gliwa A. Primary hyperparathyroidism: Skeletal and non-skeletal effects, diagnosis and management. *Maturitas*. 2011 Nov;70(3):246-55. Epub 2011 Sep 23.
- [45] Jithpratuck W, Garrett LH, Peiris AN. Treating vitamin D insufficiency in primary hyperparathyroidism: a cautionary tale. *Tenn Med*. 2011 Aug;104(7):47-9.
- [46] Espiritu RP, Kearns AE, Vickers KS, Grant C, Ryu E, Wermers RA. Depression in primary hyperparathyroidism: prevalence and benefit of surgery. *J Clin Endocrinol Metab*. 2011 Nov;96(11):E1737-45. Epub 2011 Sep 14.
- [47] Boucher BJ. Re Yu et al. The natural history of treated and untreated primary hyperparathyroidism: the Parathyroid Epidemiology and Audit Research Study. *Q J Med* 2011; 104:513-521. *QJM*. 2011 Dec;104(12):1107-8. Epub 2011 Sep 10.
- [48] Sorensen MD, Duh QY, Grogan RH, Tran TC, Stoller ML. Differences in metabolic urinary abnormalities in stone forming and nonstone forming patients with primary hyperparathyroidism. *Surgery*. 2012 Mar;151(3):477-83. Epub 2011 Sep 3.
- [49] Frazão JM, Messa P, Mellotte GJ, Geiger H, Hagen EC, Quarles LD, Kerr PG, Baños A, Dehmel B, Urena P. Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity. *Clin Nephrol*. 2011 Sep;76(3):233-43.
- [50] Stephani J, Akinli AS, von Figura G, Barth TF, Weber T, Hartmann B, Adler G, von Boyen GB. Acute Pancreatitis in a patient with hypercalcemia due to tertiary hyperparathyroidism. *Z Gastroenterol*. 2011 Sep;49(9):1263-6. Epub 2011 Sep 1.

- [51] Kovesdy CP, Lu JL, Malakauskas SM, Andress DL, Kalantar-Zadeh K, Ahmadzadeh S. Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial. *Am J Kidney Dis*. 2012 Jan;59(1):58-66. Epub 2011 Aug 31.
- [52] Hoi WH, Leow MK, Sule A, Lee HY, Mmed TA, Tay JC. Hyperparathyroidism due to eutopic PTH secretion from an ectopic intrathymic parathyroid cyst. *Ann Thorac Cardiovasc Surg*. 2011 Oct 25;17(5):511-3. Epub 2011 Jul 13.
- [53] Zitt E, Woess E, Mayer G, Lhotta K. Effect of cinacalcet on renal electrolyte handling and systemic arterial blood pressure in kidney transplant patients with persistent hyperparathyroidism. *Transplantation*. 2011 Oct 27;92(8):883-9.
- [54] Macfarlane DP, Yu N, Donnan PT, Leese GP. Should 'mild primary hyperparathyroidism' be reclassified as 'insidious': is it time to reconsider? *Clin Endocrinol (Oxf)*. 2011 Dec;75(6):730-7. doi: 10.1111/j.1365-2265.2011.04201.x.
- [55] Lucchi L, Carboni C, Stipo L, Malaguti V, Ferrari F, Graziani R, Arletti S, Graziosi C. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience. *Artif Organs*. 2011 Dec;35(12):1186-93. doi: 10.1111/j.1525-1594.2011.01270.x. Epub 2011 Aug 17.
- [56] Plosker GL. Cinacalcet: a pharmacoeconomic review of its use in secondary hyperparathyroidism in end-stage renal disease. *Pharmacoeconomics*. 2011 Sep;29(9):807-21. doi: 10.2165/11207220-000000000-00000.
- [57] Akizawa T, Kido R, Fukagawa M, Onishi Y, Yamaguchi T, Hasegawa T, Fukuhara S, Kurokawa K. Decreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism: associations with changing practice patterns. *Clin J Am Soc Nephrol*. 2011 Sep;6(9):2280-8. Epub 2011 Aug 11.
- [58] Hansen D, Rasmussen K, Danielsen H, Meyer-Hofmann H, Bacevicius E, Lauridsen TG, Madsen JK, Tougaard BG, Marckmann P, Thye-Roenn P, Nielsen JE, Kreiner S, Brandi L. No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial. *Kidney Int*. 2011 Oct;80(8):841-50. doi: 10.1038/ki.2011.226. Epub 2011 Aug 10.
- [59] Kırış A, Erem C, Kırış G, Nuhoğlu I, Karaman K, Civan N, Örem C, Durmuş I, Kutlu M. The assessment of left ventricular systolic asynchrony in patients with primary hyperparathyroidism. *Echocardiography*. 2011 Oct;28(9):955-60. doi: 10.1111/j.1540-8175.2011.01468.x. Epub 2011 Aug 9.
- [60] Maniero C, Fassina A, Guzzardo V, Lenzini L, Amadori G, Pelizzo MR, Gomez-Sanchez C, Rossi GP. Primary hyperparathyroidism with concurrent primary aldosteronism. *Hypertension*. 2011 Sep;58(3):341-6. Epub 2011 Aug 8.
- [61] Islam MZ, Viljakainen HT, Kärkkäinen MU, Saarnio E, Laitinen K, Lamberg-Allardt C. Prevalence of vitamin D deficiency and secondary hyperparathyroidism during winter in pre-menopausal Bangladeshi and Somali immigrant and ethnic Finnish women: associations with forearm bone mineral density. *Br J Nutr*. 2012 Jan;107(2):277-83. Epub 2011 Aug 9.
- [62] Padmanabhan H. Outpatient management of primary hyperparathyroidism. *Am J Med*. 2011 Oct;124(10):911-4. Epub 2011 Aug 3.
- [63] Rudofsky G, Tsioga M, Reismann P, Leowardi C, Kopf S, Grafe IA, Nawroth PP, Isermann B. Transient hyperthyroidism after surgery for secondary hyperparathyroidism: a common problem. *Eur J Med Res*. 2011 Aug 8;16(8):375-80.

- [64] Jain SK, Roy SP, Nagi ON. Alendronate induced femur fracture complicated with secondary hyperparathyroidism. *Mymensingh Med J.* 2011 Jul;20(3):501-6.
- [65] Park JH, Kang SW, Jeong JJ, Nam KH, Chang HS, Chung WY, Park CS. Surgical treatment of tertiary hyperparathyroidism after renal transplantation: a 31-year experience in a single institution. *Endocr J.* 2011 Oct 29;58(10):827-33. Epub 2011 Jul 30.
- [66] Isaksen T, Nielsen CS, Christensen SE, Nissen PH, Heickendorff L, Mosekilde L. Forearm bone mineral density in familial hypocalciuric hypercalcemia and primary hyperparathyroidism: a comparative study. *Calcif Tissue Int.* 2011 Oct;89(4):285-94. doi: 10.1007/s00223-011-9517-x. Epub 2011 Jul 22.
- [67] Lieberman SM, Vouyiouklis M, Elangovan S, Morris LG. Image of the month. Tertiary hyperparathyroidism after parathyroidectomy with autotransplantation. *Arch Surg.* 2011 Jul;146(7):879-80.
- [68] Bellavia M, Gioviale MC, Damiano G, Palumbo VD, Cacciabaudo F, Altomare R, Buscemi G, Lo Monte AI. Is secondary hyperparathyroidism-related myelofibrosis a negative prognostic factor for kidney transplant outcome? *Med Hypotheses.* 2011 Oct;77(4):557-9. Epub 2011 Jul 16.
- [69] Agorastos A, Weinas A, Agorastos AD, Wiedemann K. Psychosis-induced vitamin D deficiency with secondary hyperparathyroidism and osteoporotic fractures. *Gen Hosp Psychiatry.* 2011 Nov-Dec;33(6):641.e3-5. Epub 2011 Jul 16.
- [70] Nagar S, Reid D, Czako P, Long G, Shanley C. Outcomes analysis of intraoperative adjuncts during minimally invasive parathyroidectomy for primary hyperparathyroidism. *Am J Surg.* 2012 Feb;203(2):177-81. Epub 2011 Jul 14.
- [71] De Rosa A, Rinaldi C, Tucci T, Pappatà S, Rossi F, Morra VB, Faggiano A, Colao A, De Michele G. Co-existence of primary hyperparathyroidism and Parkinson's disease in three patients: an incidental finding? *Parkinsonism Relat Disord.* 2011 Dec;17(10):771-3. Epub 2011 Jul 5.
- [72] Bargren AE, Repplinger D, Chen H, Sippel RS. Can biochemical abnormalities predict symptomatology in patients with primary hyperparathyroidism? *J Am Coll Surg.* 2011 Sep;213(3):410-4. Epub 2011 Jul 1.
- [73] Meola M, Petrucci I, Colombini E, Barsotti G. Use of ultrasound to assess the response to therapy for secondary hyperparathyroidism. *Am J Kidney Dis.* 2011 Sep;58(3):485-91. Epub 2011 Jun 29.
- [74] Schreinemakers JM, Pieterman CR, Scholten A, Vriens MR, Valk GD, Rinkes IH. The optimal surgical treatment for primary hyperparathyroidism in MEN1 patients: a systematic review. *World J Surg.* 2011 Sep;35(9):1993-2005.
- [75] Alhefdhi A, Pinchot SN, Davis R, Sippel RS, Chen H. The necessity and reliability of intraoperative parathyroid hormone (PTH) testing in patients with mild hyperparathyroidism and PTH levels in the normal range. *World J Surg.* 2011 Sep;35(9):2006-9.
- [76] Ikegami S, Kamimura M, Uchiyama S, Kato H. Women with insufficient 25-hydroxyvitamin D without secondary hyperparathyroidism have altered bone turnover and greater incidence of vertebral fractures. *J Orthop Sci.* 2011 Sep;16(5):573-80. Epub 2011 Jun 29.

- [77] van Ginhoven TM, Morks AN, Schepers T, de Graaf PW, Smit PC. Surgeon-performed ultrasound as preoperative localization study in patients with primary hyperparathyroidism. *Eur Surg Res.* 2011;47(2):70-4. Epub 2011 Jun 23.
- [78] Christensen MH, Dankel SN, Nordbø Y, Varhaug JE, Almås B, Lien EA, Mellgren G. Primary hyperparathyroidism influences the expression of inflammatory and metabolic genes in adipose tissue. *PLoS One.* 2011;6(6):e20481. Epub 2011 Jun 17.
- [79] Stubbs JR, Wetmore JB. Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism? *Semin Dial.* 2011 May-Jun;24(3):298-306. doi: 10.1111/j.1525-139X.2011.00935.x.
- [80] Fujii T, Yamaguchi S, Yajima R, Tsutsumi S, Uchida N, Asao T, Oriuchi N, Kuwano H. Use of a handheld, semiconductor (cadmium zinc telluride)-based gamma camera in navigation surgery for primary hyperparathyroidism. *Am Surg.* 2011 Jun;77(6):690-3.
- [81] Kaji H, Imanishi Y, Sugimoto T, Seino S. Comparisons of serum sclerostin levels among patients with postmenopausal osteoporosis, primary hyperparathyroidism and osteomalacia. *Exp Clin Endocrinol Diabetes.* 2011 Jul;119(7):440-4. doi: 10.1055/s-0031-1275661. Epub 2011 Jun 10.
- [82] Frank-Raue K, Haag C, Schulze E, Keuser R, Raue F, Dralle H, Lorenz K. CDC73-related hereditary hyperparathyroidism: five new mutations and the clinical spectrum. *Eur J Endocrinol.* 2011 Sep;165(3):477-83. Epub 2011 Jun 7.
- [83] Rejnmark L, Vestergaard P, Mosekilde L. Nephrolithiasis and renal calcifications in primary hyperparathyroidism. *J Clin Endocrinol Metab.* 2011 Aug;96(8):2377-85. Epub 2011 Jun 6.
- [84] Schillaci G, Pucci G, Pirro M, Monacelli M, Scarponi AM, Manfredelli MR, Rondelli F, Avenia N, Mannarino E. Large-artery stiffness: a reversible marker of cardiovascular risk in primary hyperparathyroidism. *Atherosclerosis.* 2011 Sep;218(1):96-101. Epub 2011 May 18.
- [85] Mannstadt M, Holick E, Zhao W, Jüppner H. Mutational analysis of GCMB, a parathyroid-specific transcription factor, in parathyroid adenoma of primary hyperparathyroidism. *J Endocrinol.* 2011 Aug;210(2):165-71. Epub 2011 Jun 3.

IntechOpen



Topics in Thoracic Surgery

Edited by Prof. Paulo Cardoso

ISBN 978-953-51-0010-2

Hard cover, 486 pages

Publisher InTech

Published online 15, February, 2012

Published in print edition February, 2012

Thoracic Surgery congregates topics and articles from many renowned authors around the world covering several different topics. Unlike the usual textbooks, Thoracic Surgery is a conglomerate of different topics from Pre-operative Assessment, to Pulmonary Resection for Lung Cancer, chest wall procedures, lung cancer topics featuring aspects of VATS major pulmonary resections along with traditional topics such as Pancoast tumors and recurrence patterns of stage I lung disease, hyperhidrosis, bronchiectasis, lung transplantation and much more. This Open Access format is a novel method of sharing thoracic surgical information provided by authors worldwide and it is made accessible to everyone in an expedite way and with an excellent publishing quality.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Dariusz Sagan, Jerzy S. Tarach, Andrzej Nowakowski, Maria Klatka, Elżbieta Czekajska-Chehab, Andrzej Drop, Beata Chrapko and Janusz Klatka (2012). Mediastinal Parathyroidectomy: Preoperative Management of Hyperparathyroidism, Topics in Thoracic Surgery, Prof. Paulo Cardoso (Ed.), ISBN: 978-953-51-0010-2, InTech, Available from: <http://www.intechopen.com/books/topics-in-thoracic-surgery/mediastinal-parathyroidectomy-preoperative-management-of-hyperparathyroidism>

INTECH
open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](https://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

IntechOpen

IntechOpen